- Home
- CRK vs DNTH Comparison
CRK vs DNTH Comparison
Compare CRK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRK | DNTH |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRK | DNTH |
|---|---|---|
| Price | $13.25 | $90.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $22.20 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.8M | 425.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $555,231,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.91 | $29.48 |
| P/E Ratio | $35.74 | ★ N/A |
| Revenue Growth | ★ 32.11 | N/A |
| 52 Week Low | $12.84 | $16.77 |
| 52 Week High | $31.17 | $96.50 |
Technical Indicators
Market Signals| Indicator | CRK | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 59.23 |
| Support Level | N/A | $81.16 |
| Resistance Level | $15.22 | $96.50 |
| Average True Range (ATR) | 0.63 | 4.45 |
| MACD | -0.03 | 0.25 |
| Stochastic Oscillator | 19.12 | 85.05 |
Price Performance
Historical ComparisonAbout CRK Comstock Resources Inc.
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.